News and Trends 14 Jul 2023 BioGeneration Ventures closes BGV Fund V at €150M BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […] July 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Expert Advice 2 Mar 2023 5 steps to strategic partnerships for healthtech startups By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […] March 2, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Lyvgen and Bristol Myers Squibb commitment to transform cancer care Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with Bristol Myers Squibb, nivolumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC). “Lyvgen clinical collaboration with Bristol Myers Squibb underscores our commitment to exploring combination regimens from our portfolio with complementary mechanisms of action […] November 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2022 A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of […] October 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix (ECM) biomarker, PRO-C6, as a potential next-generation biomarker for trial enrichment in patients with heart failure with preserved ejection fraction (HFpEF). The paper is entitled “Endotrophin, a collagen VI formation-derived peptide, in Heart Failure.” The […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Treatment for adults with moderate to severe psoriasis approved by FDA A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by the U.S. Food and Drug Administration (FDA). Bristol Myers Squibb made the announcement today (September 12) that its allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyku (deucravacitinib) had been approved based on results from a phase […] September 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2022 Amphista Lands Megadeals to Smash Cancer using Protein Degradation As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […] May 5, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2021 BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […] April 29, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2017 Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market? Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […] March 28, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2017 Will BMS Take Over a Danish Biotech in a Massive €400M Deal? Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […] March 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2017 French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial Innate Pharma’s checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow to the company’s stock. When the stock market opened this morning, Innate Pharma‘s stock went down by almost 25%. The company had just announced the results of a Phase II trial that failed to prove its […] February 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […] December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email